Trial Questions Role of Dual Immunotherapy in First-Line NSCLC
Nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) did not improve overall survival (OS) and
Nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) did not improve overall survival (OS) and
A healthier diet is associated with serum metabolite concentrations indicative of better cardiovascular health already in school-aged children, a recent study from the University of
The nine biosimilars competing with AbbVie’s megablockbuster Humira have tried everything from exactly imitating the latest version of brand-name Humira to taking more than 80%